Literature DB >> 23091201

Drug-induced arrhythmia: pharmacogenomic prescribing?

Elijah R Behr1, Dan Roden.   

Abstract

Drug-induced Torsades de Pointes is a rare, unpredictable, and life-threatening serious adverse event. It can be caused by both cardiac and non-cardiac drugs and has become a major issue in novel drug development and for the regulatory authorities. This review describes the problem, predisposing factors, and the underlying genetic predisposition as it is understood currently. The future potential for pharmacogenomic-guided and personalized prescription to prevent drug-induced Torsades de Pointes is discussed. Database searches utilized reports from www.qtdrugs.org up to January 2012, case reports and articles from www.pubmed.com up to January 2012, and the British National Formulary edition at www.bnf.org.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23091201      PMCID: PMC3538275          DOI: 10.1093/eurheartj/ehs351

Source DB:  PubMed          Journal:  Eur Heart J        ISSN: 0195-668X            Impact factor:   29.983


  66 in total

1.  Risk of torsades de pointes with non-cardiac drugs. Doctors need to be aware that many drugs can cause qt prolongation.

Authors:  Y G Yap; J Camm
Journal:  BMJ       Date:  2000-04-29

2.  The potential for QT prolongation and pro-arrhythmia by non-anti-arrhythmic drugs: clinical and regulatory implications. Report on a Policy Conference of the European Society of Cardiology.

Authors:  W Haverkamp; G Breithardt; A J Camm; M J Janse; M R Rosen; C Antzelevitch; D Escande; M Franz; M Malik; A Moss; R Shah
Journal:  Cardiovasc Res       Date:  2000-08       Impact factor: 10.787

Review 3.  The potential for QT prolongation and proarrhythmia by non-antiarrhythmic drugs: clinical and regulatory implications. Report on a policy conference of the European Society of Cardiology.

Authors:  W Haverkamp; G Breithardt; A J Camm; M J Janse; M R Rosen; C Antzelevitch; D Escande; M Franz; M Malik; A Moss; R Shah
Journal:  Eur Heart J       Date:  2000-08       Impact factor: 29.983

4.  The International Serious Adverse Events Consortium (iSAEC) phenotype standardization project for drug-induced torsades de pointes.

Authors:  Elijah R Behr; Craig January; Eric Schulze-Bahr; Andrew A Grace; Stefan Kääb; Monica Fiszman; Shaniece Gathers; Shaavhrée Buckman; Ashraf Youssef; Munir Pirmohamed; Dan Roden
Journal:  Eur Heart J       Date:  2012-07-02       Impact factor: 29.983

5.  QTc-interval abnormalities and psychotropic drug therapy in psychiatric patients.

Authors:  J G Reilly; S A Ayis; I N Ferrier; S J Jones; S H Thomas
Journal:  Lancet       Date:  2000-03-25       Impact factor: 79.321

6.  Allelic variants in long-QT disease genes in patients with drug-associated torsades de pointes.

Authors:  Ping Yang; Hideaki Kanki; Benoit Drolet; Tao Yang; Jian Wei; Prakash C Viswanathan; Stefan H Hohnloser; Wataru Shimizu; Peter J Schwartz; Marshall Stanton; Katherine T Murray; Kris Norris; Alfred L George; Dan M Roden
Journal:  Circulation       Date:  2002-04-23       Impact factor: 29.690

7.  A common polymorphism associated with antibiotic-induced cardiac arrhythmia.

Authors:  F Sesti; G W Abbott; J Wei; K T Murray; S Saksena; P J Schwartz; S G Priori; D M Roden; A L George; S A Goldstein
Journal:  Proc Natl Acad Sci U S A       Date:  2000-09-12       Impact factor: 11.205

Review 8.  QT-interval prolongation by non-cardiac drugs: lessons to be learned from recent experience.

Authors:  F De Ponti; E Poluzzi; N Montanaro
Journal:  Eur J Clin Pharmacol       Date:  2000-04       Impact factor: 2.953

9.  Evidence for a cardiac ion channel mutation underlying drug-induced QT prolongation and life-threatening arrhythmias.

Authors:  C Napolitano; P J Schwartz; A M Brown; E Ronchetti; L Bianchi; A Pinnavaia; G Acquaro; S G Priori
Journal:  J Cardiovasc Electrophysiol       Date:  2000-06

10.  Novel rare variants in congenital cardiac arrhythmia genes are frequent in drug-induced torsades de pointes.

Authors:  A H Ramirez; C M Shaffer; J T Delaney; D P Sexton; S E Levy; M J Rieder; D A Nickerson; A L George; D M Roden
Journal:  Pharmacogenomics J       Date:  2012-05-15       Impact factor: 3.550

View more
  29 in total

Review 1.  Genetic testing for inherited cardiac disease.

Authors:  Arthur A M Wilde; Elijah R Behr
Journal:  Nat Rev Cardiol       Date:  2013-07-30       Impact factor: 32.419

Review 2.  Clinical association between pharmacogenomics and adverse drug reactions.

Authors:  Zhi-Wei Zhou; Xiao-Wu Chen; Kevin B Sneed; Yin-Xue Yang; Xueji Zhang; Zhi-Xu He; Kevin Chow; Tianxin Yang; Wei Duan; Shu-Feng Zhou
Journal:  Drugs       Date:  2015-04       Impact factor: 9.546

Review 3.  Finding the rhythm of sudden cardiac death: new opportunities using induced pluripotent stem cell-derived cardiomyocytes.

Authors:  Karim Sallam; Yingxin Li; Philip T Sager; Steven R Houser; Joseph C Wu
Journal:  Circ Res       Date:  2015-06-05       Impact factor: 17.367

Review 4.  Inherited Arrhythmias: Of Channels, Currents, and Swimming.

Authors:  Maura M Zylla; Dierk Thomas
Journal:  Biophys J       Date:  2016-03-08       Impact factor: 4.033

5.  Voriconazole-induced QT prolongation among hemato-oncologic patients: clinical characteristics and risk factors.

Authors:  I Gueta; R Loebstein; N Markovits; Y Kamari; H Halkin; G Livni; H Yarden-Bilavsky
Journal:  Eur J Clin Pharmacol       Date:  2017-06-17       Impact factor: 2.953

Review 6.  Pharmacological treatment of acquired QT prolongation and torsades de pointes.

Authors:  Simon H L Thomas; Elijah R Behr
Journal:  Br J Clin Pharmacol       Date:  2015-10-26       Impact factor: 4.335

Review 7.  The genetics of pro-arrhythmic adverse drug reactions.

Authors:  Evmorfia Petropoulou; Yalda Jamshidi; Elijah R Behr
Journal:  Br J Clin Pharmacol       Date:  2014-04       Impact factor: 4.335

Review 8.  Ionic mechanisms of arrhythmogenesis.

Authors:  Justus M Anumonwo; Sandeep V Pandit
Journal:  Trends Cardiovasc Med       Date:  2015-01-16       Impact factor: 6.677

9.  Sudden unexpected death in epilepsy genetics: Molecular diagnostics and prevention.

Authors:  Alica M Goldman; Elijah R Behr; Christopher Semsarian; Richard D Bagnall; Sanjay Sisodiya; Paul N Cooper
Journal:  Epilepsia       Date:  2016-01       Impact factor: 5.864

Review 10.  Assessing cardiovascular drug safety for clinical decision-making.

Authors:  Raymond L Woosley; Klaus Romero
Journal:  Nat Rev Cardiol       Date:  2013-04-16       Impact factor: 32.419

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.